GlassScriptPhysician profile
Ashton Connor
NPI 1437719317
$7,330.10
in general payments reported to CMS, 2019-2025
23 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $601 · 2023: $5,298 · 2024: $821 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881 · Consulting Fee: $1,965 · Travel and Lodging: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.62 |
| Consulting Fee | $1,965.00 |
| Travel and Lodging | $1,883.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,456.33 | 2022-2025 | |
| Transmedics, INC. | $1,312.43 | 2023 | Organ Care System |
| Intuitive Surgical, INC. | $790.50 | 2022-2023 | Da Vinci Surgical System |
| Abbvie INC. | $751.96 | 2022-2025 | Avycaz, Teflaro |
| Merck Sharp & Dohme LLC | $299.39 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.77 | 2023-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $217.68 | 2022-2025 | Ultomiris, Soliris |
| Tela Bio, INC. | $184.52 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Takeda Pharmaceuticals U.S.A., INC. | $170.89 | 2022-2025 | Livtencity |
| Astrazeneca Pharmaceuticals LP | $169.97 | 2023-2025 | |
| Aroa Biosurgery Incorporated | $145.09 | 2025 | |
| Novo Nordisk INC | $119.93 | 2022 | |
| Incyte Corporation | $77.83 | 2022-2024 | Pemazyre |
| Teleflex LLC | $70.89 | 2022 | |
| Smith+Nephew, INC. | $61.98 | 2023-2024 | Stravix Pl, Oasis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $55.40 | 2023-2024 | Sir-Spheres Microspheres |
| Octapharma USA, INC. | $54.28 | 2024 | Balfaxar |
| Baxter Healthcare | $42.81 | 2025 | Perclot |
| Davol INC. | $41.44 | 2023 | Phasix Mesh |
| Mallinckrodt Hospital Products INC. | $23.43 | 2025 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $18.90 | 2025 | |
| Melinta Therapeutics, LLC | $15.00 | 2024 | Rezzayo |
| Straumann USA LLC | $14.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.